Ami obtained a First Class (Hons) BSc degree in Biomedical Science from the University of Sussex. After graduating in 2016, she worked as an Analytical Scientist for Bioventix, a biotech company based in Surrey that specializes in the manufacture and supply of highly specific sheep monoclonal antibodies for use in clinical diagnostics, drug testing, and research. In September 2018, Ami joined the CDT in Advanced Therapeutics and Nanomedicines, and has since completed two training projects. The first titled "Evaluation of Cell Viabiltiy in Hydrogels" under the supervision of Dr Maria Marlow, Dr Lisa White and Dr Mischa Zelzer, and is currently working on the second training project at AstraZeneca.the second titled "Comparison of traditional and novel tableting excipients: Physical, compaction and dissolution properties" at AstraZeneca. She has now begun work on her PhD project titled "Novel formulations for the delivery of therapeutic cells for traumatic brain injury."
Ami's PhD project is titled "Novel formulations for the delivery of therapeutic cells for traumatic brain injury."
Supervised by Dr Maria Marlow, Dr Lisa White, Dr James Phillips and Dr Steve Brocchini.
The first training project was completed under the supervision of Dr Maria Marlow, Dr Mischa Zelzer, and Dr Lisa White. This project was titled "Evaluation of Cell Viability in Hydrogels", and involved optimizing cell viability assays for the evaluation of hydrogels as encapsulation materials for cells, including a nucleoside hydrogel which shows potential as an injectable hydrogel due to it's self-healing properties.
The second project was completed at AstraZeneca and was title "Comparison of traditional and novel tableting excipients: Physical, compaction and dissolution properties."
University of NottinghamUniversity Park
Nottingham, NG7 2RD
For all enquiries please visit:
Connect with the University of Nottingham through social media and our blogs.
Campus maps | More contact information | Jobs